Traders purchased shares of CVS Health Corporation (NYSE:CVS) on weakness during trading on Friday. $154.43 million flowed into the stock on the tick-up and $105.07 million flowed out of the stock on the tick-down, for a money net flow of $49.36 million into the stock. Of all equities tracked, CVS Health Corporation had the 24th highest net in-flow for the day. CVS Health Corporation traded down ($0.67) for the day and closed at $92.72

A number of analysts have weighed in on the stock. Mizuho restated a “buy” rating and issued a $117.00 target price (up previously from $104.00) on shares of CVS Health Corporation in a research report on Wednesday, May 4th. Royal Bank Of Canada restated an “outperform” rating and issued a $115.00 target price (up previously from $110.00) on shares of CVS Health Corporation in a research report on Wednesday, May 4th. FBR & Co restated a “buy” rating on shares of CVS Health Corporation in a research report on Saturday, May 14th. Deutsche Bank AG raised their target price on shares of CVS Health Corporation from $99.00 to $105.00 and gave the company a “hold” rating in a research report on Wednesday, June 22nd. Finally, Leerink Swann restated a “buy” rating and issued a $110.00 target price on shares of CVS Health Corporation in a research report on Thursday, May 5th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $112.98.

The company has a market cap of $99.58 billion and a PE ratio of 20.15. The firm’s 50-day moving average price is $95.28 and its 200-day moving average price is $98.22.

CVS Health Corporation (NYSE:CVS) last issued its quarterly earnings results on Tuesday, May 3rd. The pharmacy operator reported $1.18 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.16 by $0.02. During the same quarter in the previous year, the business earned $1.14 earnings per share. The business earned $43.20 billion during the quarter, compared to the consensus estimate of $43.01 billion. The firm’s revenue was up 18.9% compared to the same quarter last year. On average, equities analysts anticipate that CVS Health Corporation will post $5.82 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 1st. Investors of record on Thursday, July 21st will be paid a $0.425 dividend. The ex-dividend date of this dividend is Tuesday, July 19th. This represents a $1.70 annualized dividend and a dividend yield of 1.83%.

In other CVS Health Corporation news, CEO Larry J. Merlo sold 38,247 shares of the firm’s stock in a transaction dated Thursday, May 5th. The shares were sold at an average price of $105.00, for a total transaction of $4,015,935.00. Following the completion of the sale, the chief executive officer now directly owns 280,381 shares in the company, valued at approximately $29,440,005. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Troyen A. Brennan sold 7,517 shares of the firm’s stock in a transaction dated Thursday, May 5th. The shares were sold at an average price of $105.00, for a total transaction of $789,285.00. Following the sale, the executive vice president now owns 69,601 shares of the company’s stock, valued at $7,308,105. The disclosure for this sale can be found here.

A number of hedge funds have recently added to or reduced their stakes in CVS. Montag A & Associates Inc. raised its stake in CVS Health Corporation by 1.4% in the fourth quarter. Montag A & Associates Inc. now owns 63,170 shares of the pharmacy operator’s stock worth $6,176,000 after buying an additional 875 shares in the last quarter. BlackRock Investment Management LLC raised its stake in CVS Health Corporation by 4.6% in the fourth quarter. BlackRock Investment Management LLC now owns 4,823,258 shares of the pharmacy operator’s stock worth $471,570,000 after buying an additional 213,785 shares in the last quarter. BlackRock Advisors LLC raised its stake in CVS Health Corporation by 27.3% in the fourth quarter. BlackRock Advisors LLC now owns 4,896,947 shares of the pharmacy operator’s stock worth $478,774,000 after buying an additional 1,049,464 shares in the last quarter. Marco Investment Management LLC raised its stake in CVS Health Corporation by 2.4% in the fourth quarter. Marco Investment Management LLC now owns 54,084 shares of the pharmacy operator’s stock worth $5,288,000 after buying an additional 1,250 shares in the last quarter. Finally, KBC Group NV raised its stake in CVS Health Corporation by 1.5% in the fourth quarter. KBC Group NV now owns 203,744 shares of the pharmacy operator’s stock worth $19,920,000 after buying an additional 3,013 shares in the last quarter.

CVS Health Corporation, together with its subsidiaries, is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail Pharmacy and Corporate. The Pharmacy Services segment provides a range of pharmacy benefit management (PBM) services and operates under the CVS/caremark Pharmacy Services, Novologix and Navarro Health Services names.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.